公开(公告)号：US20240325351A1

公开(公告)日：2024-10-03

申请号：US18619547

申请日：2024-03-28

Applicant: Cybin UK Ltd.

Inventor： Peter RANDS ,  Carol ROUTLEDGE ,  Ellen JAMES ,  Tiffanie BENWAY ,  Zelah JOEL ,  Victoria ATTWOOLL ,  Meghan GOOD

IPC: A61K31/4045 ,  A61K9/00 ,  A61K45/06 ,  A61P25/24

CPC classification number: A61K31/4045 ,  A61K45/06 ,  A61P25/24 ,  A61K9/0019 ,  A61K9/0053

Abstract: The invention relates to a combination, combination for use, method for treating, kit, dosage regime, delivery device, method of adjuvant treatment, short-duration psychedelic agent for use, or parenteral formulation for use in the treatment of a psychiatric disorder in a patient. In particular, the invention relates to the administration of a short-duration psychedelic agent in combination with a monoamine antidepressant, such as a selective serotonin reuptake inhibitor (SSRI).

公开(公告)号：US20240342101A1

公开(公告)日：2024-10-17

申请号：US18748483

申请日：2024-06-20

Applicant: Cybin UK Ltd

Inventor： Peter RANDS ,  Tiffanie BENWAY ,  Zelah JOEL ,  Marie LAYZELL ,  Ellen JAMES

IPC: A61K9/48 ,  A61K9/00 ,  A61K9/20 ,  A61K9/50 ,  A61K31/4045 ,  C07B59/00 ,  C07D209/16

CPC classification number: A61K9/485 ,  A61K9/0053 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/5057 ,  A61K31/4045 ,  C07B59/002 ,  C07D209/16 ,  C07B2200/05

Abstract: The present invention relates to a solid dosage form comprising two or more compounds selected from N,N-dimethyltryptamine and its deuterated analogues and pharmaceutically acceptable salts thereof, and methods of treatment (e.g., of a psychiatric disorder or a neurological disorder) comprising administering the solid dosage form to a patient in need thereof.

公开(公告)号：US20240217929A1

公开(公告)日：2024-07-04

申请号：US18602171

申请日：2024-03-12

Applicant: CYBIN UK LTD

Inventor： Peter RANDS ,  George KNIGHT ,  Richard CHUBB ,  Derek LONDESBROUGH ,  Tiffanie BENWAY ,  Zelah JOEL

IPC: C07D209/16 ,  C07D209/20

CPC classification number: C07D209/16 ,  C07D209/20 ,  C07B2200/05

Abstract: Syntheses of compounds of Formula Ill from compounds of Formula I via compounds of Formula II are described, as well as particular compounds of Formula III, or pharmaceutically acceptable salts thereof, compositions comprising such compounds, and uses thereof. For example, certain of these compounds and compositions of Formula III have uses in the treatment of psychiatric or neurological disorders.

公开(公告)号：US20250042852A1

公开(公告)日：2025-02-06

申请号：US18921515

申请日：2024-10-21

Applicant: CYBIN UK LTD

Inventor： Peter RANDS ,  George KNIGHT ,  Richard CHUBB ,  Derek LONDESBROUGH ,  Tiffanie BENWAY ,  Zelah JOEL

IPC: C07D209/16 ,  C07D209/20

Abstract: The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, as well as compositions comprising such compounds. These compounds and compositions have uses in the treatment of psychiatric or neurological disorders. Compounds of formula I comprise at least one deuterium atom at the α-position and consequently have improved oral bioavailability relative to α-diprotic analogues.

公开(公告)号：US20250032450A1

公开(公告)日：2025-01-30

申请号：US18711130

申请日：2022-11-18

Applicant: Cybin UK Ltd.

Inventor： Peter RANDS ,  Carol ROUTLEDGE ,  Marie LAYZELL ,  Ellen JAMES ,  Zelah JOEL ,  Tiffanie BENWAY ,  Meghan GOOD

IPC: A61K31/4045 ,  A61K9/00 ,  A61K47/02 ,  A61K47/12

Abstract: The present invention relates to aqueous pharmaceutical formulations, methods for their production, and uses thereof. The aqueous pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound and water, with a pH from 5 to 6.5, preferably from about 5 to about 6, and a concentration of the optionally substituted dimethyltryptamine compound of about 10 mg/ml or greater as the freebase equivalent. These formulations can comprise an effective dose of an optionally substituted dimethyltryptamine compound for use in psychedelic assisted therapy within a volume of 5 ml or less. Such formulations are surprisingly suitable both for intramuscular injection and nebulised inhalation, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.

公开(公告)号：US20240374565A1

公开(公告)日：2024-11-14

申请号：US18779611

申请日：2024-07-22

Applicant: CYBIN UK LTD

Inventor： Peter RANDS ,  Zelah JOEL ,  Tiffanie BENWAY

IPC: A61K31/4045

Abstract: The present invention relates to compositions comprising N,N-dimethyltryptamine, deuterated N,N-dimethyltryptamine and/or partially deuterated N,N-dimethyltryptamine.
In particular, the present invention relates to compositions comprising a combination of N,N-dimethyltryptamine and 2% or more by weight of one or more deuterated N,N-dimethyltryptamine compound selected from α,α-dideutero-N,N-dimethyltryptamine and α,α,β,β-tetradeutero-N,N-dimethyltryptamine. Additional and alternative compositions of the present invention comprise a combination of N,N-dimethyltryptamine and 2% or more by weight of one or more partially deuterated N,N-dimethyltryptamine compound selected from α,β,β-trideutero-N,N-dimethyltryptamine, α,β-dideutero-N,N-dimethyltryptamine, and α-deutero-N,N-dimethyltryptamine. Methods of synthesising compositions of the present invention, and methods of use of presently described compositions in treating psychiatric or psychocognitive disorders, such as major depressive disorder, are also provided.